Literature DB >> 1352706

Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice.

J Riondel1, M Jacrot, H Fessi, F Puisieux.   

Abstract

Free taxol and liposome-encapsulated taxol were compared for their antitumoral activities on two human brain tumors serially grafted into female athymic mice in the scapular region. In the first experiment, a human glioblastoma (15th and 16th passages) was studied. In the second experiment, a fast growing human gliosarcoma (19th passage) was used. Free taxol and liposomal taxol were administered intraperitoneally, at the same dose; 12.5 mg/kg (i.e. 1/15 of the evaluated LD 50 value). In the first experiment, the treatment was performed for four consecutive days, with four courses separated by three rest periods of three days in between. Both free taxol and encapsulated taxol produced a statistically significant delay in tumor growth, and at the end of the experiment some total tumor regressions were obtained. However, liposomes were observed to be more effective in their action on the two consecutive passages of the glioblastoma, giving a marked increase of the number of total tumor regressions. In the second experiment another schedule of treatment was chosen because of the fast growth pattern of the xenografted human gliosarcoma: free taxol and liposome-encapsulated taxol were administered for five consecutive days and three courses of treatment were performed with two rest periods of two days. The two forms of taxol had a significant inhibitory effect on gliosarcoma tumor growth; as before encapsulation in liposomes was found to increase the anti-tumoral activity of taxol, although, in this case no tumor regression was observed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352706

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

1.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

2.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

3.  Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.

Authors:  Rong Zhou; Richard V Mazurchuk; Judith H Tamburlin; John M Harrold; Donald E Mager; Robert M Straubinger
Journal:  J Pharmacol Exp Ther       Date:  2009-10-27       Impact factor: 4.030

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

Authors:  Pin-Yuan Chen; Tomoko Ozawa; Daryl C Drummond; Ashish Kalra; Jonathan B Fitzgerald; Dmitri B Kirpotin; Kuo-Chen Wei; Nicholas Butowski; Michael D Prados; Mitchel S Berger; John R Forsayeth; Krystof Bankiewicz; C David James
Journal:  Neuro Oncol       Date:  2012-12-21       Impact factor: 12.300

Review 6.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

7.  Antioxidant status and lipid peroxidation in athymic mice xenografted with two types of human tumors.

Authors:  A S Gauchez; J Riondel; M Jacrot; J Calop; A Favier
Journal:  Biol Trace Elem Res       Date:  1995 Jan-Mar       Impact factor: 3.738

8.  Cytotoxicity of taxol in vitro against human and rat malignant brain tumors.

Authors:  M A Cahan; K A Walter; O M Colvin; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.

Authors:  W Roth; B Wagenknecht; C Grimmel; J Dichgans; M Weller
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.

Authors:  A J Terzis; F Thorsen; O Heese; T Visted; R Bjerkvig; O Dahl; H Arnold; G Gundersen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.